Arthur W Stange1, F Joseph Furman, Duane E Hilmas. 1. Center for Epidemiologic Research, Oak Ridge Institute for Science and Education, 9950 West 80th Avenue, Suite 17, Arvada, Colorado 80005, USA. stangea@orau.gov
Abstract
BACKGROUND: The beryllium lymphocyte proliferation test (Be-LPT) measures beryllium-specific cellular immune response, and is useful in medical surveillance of beryllium sensitivity and chronic beryllium disease (CBD). METHODS: Current and former employees (n = 12,194) of 18 United States Department of Energy (DOE) sites were tested for beryllium sensitization at four laboratories with Be-LPT expertise. Beryllium sensitized individuals were offered evaluations for CBD. The sensitivity, specificity, and positive predictive value (PPV) of the Be-LPT were determined, as was inter- and intra-laboratory agreement. RESULTS: False positives were calculated to be 1.09%, with a laboratory range of 0.00-3.35% for the 10-year investigation. Be-LPTs performed on inter-laboratory split blood specimens from sensitized individuals showed a false negative rate of 31.7%. The intra-laboratory repeatability of abnormal Be-LPT results ranged from 80.4-91.9%. The sensitivity of the Be-LPT was determined to be 0.683, with a specificity of 0.969. The PPV of one abnormal Be-LPT was 0.253. CONCLUSIONS: The Be-LPT is efficacious in medical surveillance of beryllium-exposed individuals. The PPV of the Be-LPT is comparable to other widely accepted medical tests. Confirmation of an abnormal result is recommended to assure appropriate referral for CBD medical evaluation. Copyright 2004 Wiley-Liss, Inc.
BACKGROUND: The beryllium lymphocyte proliferation test (Be-LPT) measures beryllium-specific cellular immune response, and is useful in medical surveillance of beryllium sensitivity and chronic beryllium disease (CBD). METHODS: Current and former employees (n = 12,194) of 18 United States Department of Energy (DOE) sites were tested for beryllium sensitization at four laboratories with Be-LPT expertise. Beryllium sensitized individuals were offered evaluations for CBD. The sensitivity, specificity, and positive predictive value (PPV) of the Be-LPT were determined, as was inter- and intra-laboratory agreement. RESULTS: False positives were calculated to be 1.09%, with a laboratory range of 0.00-3.35% for the 10-year investigation. Be-LPTs performed on inter-laboratory split blood specimens from sensitized individuals showed a false negative rate of 31.7%. The intra-laboratory repeatability of abnormal Be-LPT results ranged from 80.4-91.9%. The sensitivity of the Be-LPT was determined to be 0.683, with a specificity of 0.969. The PPV of one abnormal Be-LPT was 0.253. CONCLUSIONS: The Be-LPT is efficacious in medical surveillance of beryllium-exposed individuals. The PPV of the Be-LPT is comparable to other widely accepted medical tests. Confirmation of an abnormal result is recommended to assure appropriate referral for CBD medical evaluation. Copyright 2004 Wiley-Liss, Inc.
Authors: Andrew P Fontenot; Brent E Palmer; Andrew K Sullivan; Fenneke G Joslin; Cara C Wilson; Lisa A Maier; Lee S Newman; Brian L Kotzin Journal: J Clin Invest Date: 2005-09-08 Impact factor: 14.808
Authors: Carrie A Thomas; Rachel L Bailey; Michael S Kent; David C Deubner; Kathleen Kreiss; Christine R Schuler Journal: Public Health Rep Date: 2009 Jul-Aug Impact factor: 2.792
Authors: James A Snyder; Eugene Demchuk; Erin C McCanlies; Christine R Schuler; Kathleen Kreiss; Michael E Andrew; Bonnie L Frye; James S Ensey; Marcia L Stanton; Ainsley Weston Journal: J R Soc Interface Date: 2008-07-06 Impact factor: 4.118
Authors: Ellen P Donovan; Marc E Kolanz; David A Galbraith; Pamela S Chapman; Dennis J Paustenbach Journal: Int Arch Occup Environ Health Date: 2007-05-05 Impact factor: 3.015